BioCardia

320 Soquel Way
Sunnyvale, CA 94085
Toll-free: (800) 624-1179
Phone: (650) 226-0120
Fax: (650) 631-3731

For general inquiries, please email: info@biocardia.com

For order submisions, please email: orders@biocardia.com

For investor inquiries, please email: investors@biocardia.com

press releases

18 Sep
2024 BioCardia Regains Full Compliance with Nasdaq Listing Requirements
09 Sep
2024 BioCardia Announces Closing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
30 Aug
2024 BioCardia Announces Pricing of Upsized $7.2 Million Public Offering Priced At-The-Market Under Nasdaq Rules
29 Aug
2024 BioCardia Announces FDA Market Clearance of Morph® DNA™ Steerable Introducer Product Family
21 Aug
2024 FDA Approves CardiAMP® Heart Failure II Protocol Amendment to Use Proprietary Cell Population Analysis Screening to Define Treatment
13 Aug
2024 BioCardia Reports Second Quarter 2024 Business Highlights and Financial Results
Have questions?
CALL US NOW
: (800) 624-1179
Have questions?
EMAIL US NOW
: info@biocardia.com

biocardia takes a new and comprehensive
approach to heart failure

By introducing patient screening and highly-efficient delivery to stem cell therapy, the company seeks to increase the likelihood of treatment success, enabling more patients to return to the things they love.
CLINICAL TRIALS